The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Kornilova E.B.
Research Institute for Health Care Organization and Medical Management of the Moscow Healthcare Department, Moscow, Russia
Polyakova K.I.
Research Institute for Health Care Organization and Medical Management of the Moscow Healthcare Department, Moscow, Russia
Shkurko T.V.
Research Institute for Health Care Organization and Medical Management of the Moscow Healthcare Department, Moscow, Russia;
Pirogov Russian National Medical Research University, Ministry of Health of Russia, Moscow, Russia
Kniazev O.V.
GBUZ "Moskovskiĭ klinicheskiĭ nauchno-prakticheskiĭ tsentr" Departamenta zdravookhraneniia Moskvy
Ermolaeva A.D.
Research Institute for Health Care Organization and Medical Management of the Moscow Healthcare Department, Moscow, Russia;
Loginov Moscow Clinical Scientific and Practical Center of the Moscow Healthcare Department, Moscow, Russia ,Sechenov First Moscow State Medical University Ministry of Health of Russia, Moscow, Russia
Davydovskaya M.V.
Research and Practical Centre for Clinical Investigations and Evaluation of Medical Technologies, Moscow Health Department, Moscow, Russia
Ermolaeva T.N.
Research Institute for Health Care Organization and Medical Management of the Moscow Healthcare Department, Moscow, Russia
Fisun A.G.
Research Institute for Health Care Organization and Medical Management of the Moscow Healthcare Department, Moscow, Russia
Economic rationale for administration of vedolizumab in patients with inflammatory bowel disease in Moscow
Journal: Russian Journal of Evidence-Based Gastroenterology. 2019;8(3): 55‑70
Read: 4870 times
To cite this article:
Kornilova EB, Polyakova KI, Shkurko TV, et al. . Economic rationale for administration of vedolizumab in patients with inflammatory bowel disease in Moscow. Russian Journal of Evidence-Based Gastroenterology.
2019;8(3):55‑70. (In Russ.)
https://doi.org/10.17116/dokgastro2019803155
Objective — to analyze financial advisability of the administration of vedolizumab with selective intestinal effect compared with TNF-α inhibitors in the treatment of adults with moderate-to-severe UC and Crohn’s disease, unsatisfactory response to medication, loss of response or intolerance to prior therapy. Material and methods. The head of the organizational and methodological department for gastroenterology of the Research Institute for Health Care Organization and Medical Management provided data for analysis. Patients with inflammatory bowel diseases receiving medication at the expense of the Moscow budget fund were studied. Three-year direct medical costs of Moscow health care for biological therapy before and after the introduction of Vedolizumab for the treatment of adults with moderate-to-severe UC and CD were calculated. There were patients with an unsatisfactory response to medication, loss of response or intolerance to prior therapy. Results. Expansion of biological drug spectrum through the inclusion of vedolizumab with shares of 3.9, 7.9 and 11.8% for CD and 2, 7.2 and 10.8% for UC in the 1st, the 2nd, and the 3rd year, respectively. This will result in economic advantage for Moscow budget fund near 1 616 966.07 rubles in the treatment of UC and 141,555.67 rubles in the treatment of CD. Clinical and economic efficacy of primary administration of Vedolizumab was demonstrated in comparison with prescription of other TNF-α inhibitors. Perspectives for further development were determined to improve the quality of medical care for Moscow residents and increase the availability of biological drugs for patients with UC and CD. Conclusion. Administration of Vedolizumab in adults with moderate-to-severe UC and CD, unsatisfactory response to medication, loss of response or intolerance to previous therapy will improve financial efficiency of Moscow healthcare and availability of therapy for patients with these diseases.
Keywords:
Authors:
Kornilova E.B.
Research Institute for Health Care Organization and Medical Management of the Moscow Healthcare Department, Moscow, Russia
Polyakova K.I.
Research Institute for Health Care Organization and Medical Management of the Moscow Healthcare Department, Moscow, Russia
Shkurko T.V.
Research Institute for Health Care Organization and Medical Management of the Moscow Healthcare Department, Moscow, Russia;
Pirogov Russian National Medical Research University, Ministry of Health of Russia, Moscow, Russia
Kniazev O.V.
GBUZ "Moskovskiĭ klinicheskiĭ nauchno-prakticheskiĭ tsentr" Departamenta zdravookhraneniia Moskvy
Ermolaeva A.D.
Research Institute for Health Care Organization and Medical Management of the Moscow Healthcare Department, Moscow, Russia;
Loginov Moscow Clinical Scientific and Practical Center of the Moscow Healthcare Department, Moscow, Russia ,Sechenov First Moscow State Medical University Ministry of Health of Russia, Moscow, Russia
Davydovskaya M.V.
Research and Practical Centre for Clinical Investigations and Evaluation of Medical Technologies, Moscow Health Department, Moscow, Russia
Ermolaeva T.N.
Research Institute for Health Care Organization and Medical Management of the Moscow Healthcare Department, Moscow, Russia
Fisun A.G.
Research Institute for Health Care Organization and Medical Management of the Moscow Healthcare Department, Moscow, Russia
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.